The Duke Clinical Research Institute (DCRI) has been chosen as the Clinical Trials Data Coordinating Center for the US National Institutes of Health’s (NIH) large-scale national research studies for long Covid treatment.

As the data coordinating centre, the institute will collaborate with the Administrative Coordinating Center of the study, RTI International, to expedite the trial process. 

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

They will also work on managing the programme-wide infrastructure of the study, set up a patient registry and initiate prevention and therapeutic multi-intervention studies at the same time in adults and children.

The data coordinating centre is part of the NIH Researching COVID to Enhance Recovery (RECOVER) initiative. 

It will support efforts across other current Covid-19 research projects such as the NIH-funded Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) studies and the RECOVER Consortium. 

This will offer researchers and people the opportunity to participate in long Covid studies and aid in advancing science on the disease’s effects on health.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Since the Covid-19 pandemic onset in 2020, the DCRI has taken the lead or took part in over 13 Covid-19-associated awards. 

It also led projects to lower virus spread in schools, improve vaccine safety, extend access to testing in underserved communities and understand the pandemic’s effects on health care workers. 

Furthermore, the institute is collaborating with the NIH to lead trials that analyse repurposed therapies to treat mild or moderate Covid-19 patients. 

The DCRI is also leading studies to assess if immune modulators can hinder overactive immune response in moderate and severe Covid-19 cases.

DCRI executive director Adrian Hernandez said: “From the onset of the pandemic, the DCRI has been at the forefront of Covid-19 research. 

“We are excited to apply our expertise in leading large-scale research programmes to find much needed answers to predict, prevent, and treat long Covid.”

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact